WIN 63759

Drug Profile

WIN 63759

Latest Information Update: 06 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi Winthrop
  • Class Anti-inflammatories; Benzoic acids
  • Mechanism of Action Leucocyte elastase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Respiratory tract disorders

Most Recent Events

  • 27 Aug 1999 Sanofi and Synthélabo have merged to form Sanofi-Synthélabo
  • 03 Jul 1997 An in vivo study has been added to the pharmacodynamics and pharmacokinetics sections
  • 12 Sep 1996 Preclinical development for Respiratory tract disorders in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top